Home » Galapagos Returns Investigational Drug to Molecure
Galapagos Returns Investigational Drug to Molecure
Molecure, a biotech company that is developing small molecule drugs for treatment of multiple incurable diseases, has regained full rights to OATD-01, its dual chitinase inhibitor, from Galapagos.
Galapagos, which is now focused on developing CAR-T therapies, is pulling out of a November 2020 partnership with Molecure and returning rights to the company’s investigational treatment for idiopathic pulmonary fibrosis and other diseases with a fibrotic component.
Molecure said it is considering going back to its original plan, which was to develop OATD-01 for treatment of patients with the inflammatory disease sarcoidosis.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May